Proteomic Research in Peritoneal Dialysis
1
Nephrology and Dialysis Unit, Department of Medicine, G. d’Annunzio University, Chieti-Pescara, SS. Annunziata Hospital, Via dei Vestini, 66013 Chieti, Italy
2
Nephrology Department, Campus Can Ruti, Germans Trias i Pujol Research Institute (IGTP), REMAR-IGTP Group, Germans Trias i Pujol University Hospital, Carretera de Can Ruti, Camí de les Escoles s/n, 08916 Barcelona, Spain
3
Department of Research and Development, CoreQuest Sagl, Tecnopolo, 6934 Bioggio, Switzerland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(15), 5489; https://doi.org/10.3390/ijms21155489
Received: 30 June 2020
/
Revised: 21 July 2020
/
Accepted: 29 July 2020
/
Published: 31 July 2020
(This article belongs to the Collection Advances in Proteomic Research)
Peritoneal dialysis (PD) is an established home care, cost-effective renal replacement therapy (RRT), which offers several advantages over the most used dialysis modality, hemodialysis. Despite its potential benefits, however, PD is an under-prescribed method of treating uremic patients. Infectious complications (primarily peritonitis) and bio-incompatibility of PD solutions are the main contributors to PD drop-out, due to their potential for altering the functional and anatomical integrity of the peritoneal membrane. To improve the clinical outcome of PD, there is a need for biomarkers to identify patients at risk of PD-related complications and to guide personalized interventions. Several recent studies have shown that proteomic investigation may be a powerful tool in the prediction, early diagnosis, prognostic assessment, and therapeutic monitoring of patients on PD. Indeed, analysis of the proteome present in PD effluent has uncovered several proteins involved in inflammation and pro-fibrotic insult, in encapsulating peritoneal sclerosis, or even in detecting early changes before any measurable modifications occur in the traditional clinical parameters used to evaluate PD efficacy. We here review the proteomic studies conducted thus far, addressing the potential use of such omics methodology in identifying potential new biomarkers of the peritoneal membrane welfare in relation to dialytic prescription and adequacy.
View Full-Text
Keywords:
end-stage renal disease; peritoneum; peritoneal dialysis; peritoneal dialysis effluent; proteomics; biomarker
▼
Show Figures
Graphical abstract
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Bonomini, M.; Borras, F.E.; Troya-Saborido, M.; Carreras-Planella, L.; Di Liberato, L.; Arduini, A. Proteomic Research in Peritoneal Dialysis. Int. J. Mol. Sci. 2020, 21, 5489. https://doi.org/10.3390/ijms21155489
AMA Style
Bonomini M, Borras FE, Troya-Saborido M, Carreras-Planella L, Di Liberato L, Arduini A. Proteomic Research in Peritoneal Dialysis. International Journal of Molecular Sciences. 2020; 21(15):5489. https://doi.org/10.3390/ijms21155489
Chicago/Turabian StyleBonomini, Mario, Francesc E. Borras, Maribel Troya-Saborido, Laura Carreras-Planella, Lorenzo Di Liberato, and Arduino Arduini. 2020. "Proteomic Research in Peritoneal Dialysis" International Journal of Molecular Sciences 21, no. 15: 5489. https://doi.org/10.3390/ijms21155489
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
